Phibro Animal Health (NASDAQ:PAHC) Sets New 52-Week High - Time to Buy?

Key Points

• Phibro Animal Health's stock recently reached a new 52-week high of $41.39 during trading, up from a previous close of $39.43.
• Analysts have set varied price targets for the company, with Bank of America at $27.00 and JPMorgan Chase at $35.00, while the consensus rating remains at "Reduce" with an average price target of $28.40.
• The company has announced a quarterly dividend payment of $0.12, yielding approximately 1.2% annually, with a dividend payout ratio of 40.68%.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $41.39 and last traded at $41.23, with a volume of 399900 shares changing hands. The stock had previously closed at $39.43.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on PAHC shares. Bank of America upped their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research note on Friday, August 29th. JPMorgan Chase & Co. raised shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and increased their price target for the company from $25.00 to $35.00 in a research report on Monday, July 7th. Zacks Research cut shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 28th. BNP Paribas raised shares of Phibro Animal Health to a "hold" rating in a research report on Monday, June 16th. Finally, BNP Paribas Exane raised shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target for the company in a research report on Monday, June 16th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $28.40.

Phibro Animal Health Stock Performance

The company's 50-day moving average price is $31.98 and its 200 day moving average price is $25.55. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. The stock has a market capitalization of $1.61 billion, a PE ratio of 33.62, a PEG ratio of 1.18 and a beta of 0.88.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its earnings results on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The firm had revenue of $378.70 million during the quarter, compared to analysts' expectations of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, equities research analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 3rd. Phibro Animal Health's dividend payout ratio (DPR) is currently 40.68%.

Insider Activity

In related news, CEO Jack Bendheim sold 14,080 shares of the stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $40.33, for a total value of $567,846.40. Following the completion of the transaction, the chief executive officer directly owned 45,400 shares in the company, valued at $1,830,982. This trade represents a 23.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 50.07% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PAHC. Northern Trust Corp increased its stake in shares of Phibro Animal Health by 7.2% in the 4th quarter. Northern Trust Corp now owns 245,110 shares of the company's stock worth $5,147,000 after acquiring an additional 16,421 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Phibro Animal Health by 31.2% in the 4th quarter. Ameriprise Financial Inc. now owns 90,782 shares of the company's stock worth $1,906,000 after acquiring an additional 21,576 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Phibro Animal Health in the 4th quarter worth about $204,000. Deutsche Bank AG increased its stake in shares of Phibro Animal Health by 90.8% in the 4th quarter. Deutsche Bank AG now owns 16,873 shares of the company's stock worth $354,000 after acquiring an additional 8,032 shares in the last quarter. Finally, Graham Capital Management L.P. bought a new position in shares of Phibro Animal Health in the 4th quarter worth about $245,000. 99.34% of the stock is currently owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.